Compare NetFlix Inc (NFLX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Viatris Inc — how do they compare? NetFlix Inc trades at $70.3 (market cap $298.01B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: NetFlix Inc is far larger — about 14.9× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 125 Days and Viatris Inc for 57 Days on average.
| NFLX | VTRS | |
|---|---|---|
Market Cap | $298.01B | $20.03B |
Volume | 45,805,108 | 14,109,977 |
Sector | Media | Health |
52-Week High | $124.13 | $18.27 |
52-Week Low | $67.06 | $9.74 |
Typical Hold Time | 125 Days | 57 Days |
Enterprise Value | $303.19B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $71.58, up 2.7% with strong fundamentals including 49.5% ROE and consistent earnings beats. The stock faces technical headwinds with bearish moving averages despite positive sentiment from institutional buying. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 25% upside potential from current levels.
Netflix presents a compelling growth story with expanding profit margins and robust cash flow generation. Key risks include intensifying streaming competition and content cost pressures. The company's scale advantages and pricing power support premium valuation, though technical indicators suggest near-term consolidation may precede further upside.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
